Evidence map›Paper›PMID 26686699›Full record

ArticleCancer medicine2016

Characteristics of cultured desmoid cells with different CTNNB1 mutation status.

Shunsuke Hamada, Hiroshi Urakawa, Eiji Kozawa, Eisuke Arai, Kunihiro Ikuta, Tomohisa Sakai, Naoki Ishiguro, Yoshihiro Nishida

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Shunsuke HamadaDepartment of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, Nagoya, Japan.
Hiroshi UrakawaDepartment of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, Nagoya, Japan.
Eiji KozawaDepartment of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, Nagoya, Japan.
Eisuke AraiDepartment of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, Nagoya, Japan.
Kunihiro IkutaDepartment of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, Nagoya, Japan.
Tomohisa SakaiDepartment of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, Nagoya, Japan.
Naoki IshiguroDepartment of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, Nagoya, Japan.
Yoshihiro NishidaDepartment of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, Nagoya, Japan.
Nagoya University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Desmoid tumors are benign mesenchymal neoplasms with a locally aggressive nature. The mutational status of β-catenin gene (CTNNB1) is presumed to affect the tumorous activity of the cells. In this study, we isolated three kinds of desmoid cell with different CTNNB1 status, and compared their characteristics. Cells were isolated from three patients with abdominal wall desmoid during surgery, all of which were resistant to meloxicam treatment. The mutational status of the CTNNB1 exon 3 was determined for both parental tumor tissues and isolated cultured cells. β-catenin expression was determined with immunohistochemistry. Responsiveness to meloxicam was investigated with MTS assay together with COX-2 immunostaining. mRNA expressions of downstream molecules of Wnt/β-catenin pathway were determined with real-time RT-PCR. Three kinds of cell isolated from desmoid tumors harboring different CTNNB1 mutation status (wild type, T41A, and S45F), all exhibited a spindle shape. These isolated cells could be cultured until the 20th passage with unchanged proliferative activity. Nuclear accumulation of β-catenin was observed in all cultured cells, particularly in those with S45F. Proliferating activity was significantly suppressed by meloxicam (25 μmol/L, P < 0.007) in all three cell cultures, of which parental desmoid was resistant to meloxicam clinically. The mRNA expressions of Axin2, c-Myc, and Cyclin D1 differently increased in the three cultured cell types as compared with those in human skin fibroblast cells (HDF). Inhibitors of Wnt/β-catenin pathway downregulated Axin2, c-Myc, and Cyclin D1 significantly. Isolated and cultured desmoid tumor cells harboring any one of the CTNNB1 mutation status had unique characteristics, and could be useful to investigate desmoid tumors with different mutation status of CTNNB1.

Indexed as

MutationAdultAntineoplastic AgentsApoptosisAxin Proteinbeta CateninCell Line, TumorCell ProliferationCyclin D1Cyclooxygenase 2Desmoid TumorsDNA Mutational AnalysisGene ExpressionGene Expression Regulation, NeoplasticGenes, mycHumansAntineoplastic AgentsAXIN2 protein, humanAxin Proteinbeta CateninCTNNB1 protein, humanCyclin D1Cyclooxygenase 2MeloxicamRNA, MessengerThiazinesThiazolesCTNNB1 mutationdesmoid tumormeloxicamWnt/β-catenin pathwayβ-Catenin

Identifiers

PMID26686699
PMCPMC4735788
OpenAlexW2287578241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.